title: Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases.
abstract: OBJECTIVE
  To study the clinical outcome of 82 cases of pancreatic neuroendocrine tumours classified according to the recent histological and prognostic classification of Capella.
  
  
  RESULTS
  Eighty-two surgical cases of pancreatic neuroendocrine tumours were examined histologically with immunohistochemical staining of paraffin sections using streptavidin-biotin complex and application of antibodies against chromogranin A and 10 hormonal peptides. Classification in four groups correlated with long follow-up and outcome of these cases. Histological examination showed 30 group I, four group II, 41 group III and seven group IV tumours. Twenty-one (70%) of group I tumours were insulinomas, whereas 25% of group III tumours were glucagonomas and 25% were unclassified. Most group IV tumours were unclassified, showing no immunohistochemical staining with any of the 10 hormonal peptides tested. Outcome was clearly correlated with tumour group. Among the 14 patients who died of the disease, four had group IV and 10 group III tumours. Thus, unclassified asymptomatic tumours without immunohistochemical staining had a poorer prognosis than asymptomatic tumours with staining.
  
  
  CONCLUSIONS
  This study validates the Capella classification as easy to apply and useful in predicting clinical outcome.
authors.affiliation: Department of Pathology, University Hospital, Paris Lariboisière, Nantes, France. mfheymann@chu-nantes.fr
authors.forename: M F
authors.initials: MF
authors.lastname: Heymann
authors.forename: M
authors.initials: M
authors.lastname: Joubert
authors.forename: J
authors.initials: J
authors.lastname: Nemeth
authors.forename: B
authors.initials: B
authors.lastname: Franc
authors.forename: J
authors.initials: J
authors.lastname: Visset
authors.forename: A
authors.initials: A
authors.lastname: Hamy
authors.forename: J
authors.initials: J
authors.lastname: le Borgne
authors.forename: J C
authors.initials: JC
authors.lastname: le Neel
authors.forename: A
authors.initials: A
authors.lastname: Murat
authors.forename: S
authors.initials: S
authors.lastname: Cordel
authors.forename: M F
authors.initials: MF
authors.lastname: le Bodic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000145:classification* / Q000175:diagnosis; D009479:Neuropeptides / Q000032:analysis; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000145:classification* / Q000175:diagnosis; D011379:Prognosis; D015203:Reproducibility of Results
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins; D009479:Neuropeptides